Dermatology

This new data indicates that dupilumab in this patient population had favorable efficacy and safety, though some unique concerns were risk of infection and eosinophilia.

Gina Mangin, MPAS, PA-C, shares take-home pearls with fellow healthcare providers, highlighting the importance of listening to the patient.

An expert in dermatological conditions discusses new treatments in the pipeline for HS, commenting on her experience with biologic treatment.

Gina Mangin, MPAS, PA-C, reviews current treatment options for patients with HS, highlighting adalimumab as well as non-FDA approved therapies.

In this recent analysis of hyperhidrosis burden on patients, prevalence of the condition and its impacts on patients demonstrate the value of exploring knowledge gaps for this disease.

An expert physician assistant in dermatology provides an overview of how HS is diagnosed, and how the diagnosis is often delayed.

Gina Mangin, MPAS, PA-C, reviews the quality of life for patients living with hidradenitis suppurativa (HS), areas of the body commonly affected by HS, as well as the most common symptoms of the disease.

An expert in dermatological conditions discusses office-based procedures that can benefit patients with HS and shares clinical pearls for the management of the disorder.

Andrew Baker PA-C, MBA, reviews unmet needs for the clinical management of moderate-to-severe HS and shares insight on novel and emerging therapies in the pipeline.

This new phase 4 data provides some valuable insights for healthcare professionals and those seeking to compare therapy options for psoriasis.

This data on a large racial and ethnic minority cohort indicated that low melanoma incidence and detection rates and more aggressive nature of cancer shows the need for greater attention.

This new research highlights the value of habit replacement intervention, supported by the fact that apparent low usefulness/efficacy of other methods for patients can often manifest in poorer retention.

A physician assistant expert in dermatological conditions comments on the use of biological therapy to manage moderate-to-severe HS in adults and adolescents and the long-term effectiveness of these agents.

Andrew Baker PA-C, MBA, provides an overview of hidradenitis suppurativa (HS), including the pathogenesis, comorbidities, and diagnosis of this inflammatory disorder.

An expert in dermatology reviews the phase 3 SUNSHINE and SUNRISE trials evaluating the use of secukinumab given in 2-week intervals in patients with HS and shares clinical pearls for managing the condition.

An expert in dermatology highlights emerging biologic therapy for the management of HS.

Renata Block, MMS, PA-C, comments on the use of biologic agents as part of immunomodulatory therapy for HS treatment.

In this interview with Dr. Baldwin, she spoke on her team’s recent research and its application to rosacea and other dermatologic conditions.

The long-awaited approval for VP-102 makes this treatment the first available therapy for the pox virus-borne skin disease.

An expert in dermatology reviews the current standard of care for treating patients with mild-to-moderate HS and discusses unmet needs in the clinical management of the condition.

Renata Block, MMS, PA-C, provides insight on the prevalence, symptoms, and predisposing factors that contribute to hidradenitis suppurativa (HS).

This new data could be valuable for follow-up appointments with patients who have cutaneous squamous cell carcinoma and for skin cancer services.

This new data on factors which may inhibit access to dermatologic care indicates the potential value for policy-makers as well as educators to make changes to fill such gaps in care.

In his interview, Dr. Amin discusses his views on the FDA’s recent approval of ritlecitinib for the treatment of adolescent patients with alopecia areata.

For this segment of her interview, Dr. Mellerio further discussed the contents of her talk on new treatment options for epidermolysis bullosa, highlighting DEB and EB simplex.